Hanmi Pharmaceutical vs Yuhan Corporation
Yuhan holds the stronger position because its licensed lung cancer drug is actively taking market share from a rival while Hanmi is distracted by an internal family control fight.
Hanmi Pharmaceutical
Korean pharma maker of long-acting peptide drugs, generics, and an obesity drug in development
Yuhan Corporation
Korea's oldest major pharma firm, now living off royalties from a lung cancer drug licensed to J&J
Dimension by dimension
| Dimension | Hanmi Pharmaceutical | Yuhan Corporation |
|---|---|---|
| Staying power of core product | Hanmi sells across diabetes, oncology and obesity drugs, giving it several income streams rather than one. | Yuhan's growth leans heavily on royalties from a single licensed lung cancer drug, Lazcluze. |
| Exposure to AI | Physical drug manufacturing and clinical licensing are not something AI tools can absorb. | Same protection applies; Yuhan's royalty and drug sales model sits outside AI's reach. |
| How easily a giant copies them | Patented drug formulations and regulatory approvals block quick copying. | Yuhan's licensed drug and its regulatory path are equally hard for a large competitor to replicate quickly. |
| Pressure from rivals | Hanmi shows no sign of losing customers to rivals; its pressure comes from an internal fight between the founding family and management. | Yuhan faces lower pressure and its combo drug is actually pulling share away from AstraZeneca's Tagrisso. |
| Financial footing | Hanmi posted about USD 1.15B in revenue with operating profit up 19.2% and net profit up 33.9%. | Yuhan posted KRW 2.1866 trillion in revenue, roughly double the operating profit of the prior year, and net profit up 235.9%. |
| Internal stability | Hanmi is dealing with a governance dispute between the founding family and current management, an added layer of uncertainty. | No such internal conflict appears in Yuhan's numbers or description. |
Questions people ask
- Is Hanmi's family dispute a bigger risk than Yuhan relying on one drug?
- Both carry real risk. Hanmi's family control fight could disrupt decision making at any time, while Yuhan's growth depends heavily on one licensed drug's continued success against rivals like AstraZeneca.
- How do Hanmi and Yuhan compare financially in 2025?
- Yuhan reported larger revenue growth and a much sharper jump in net profit, up 235.9%, compared with Hanmi's 33.9% net profit growth. Both companies grew operating profit, but Yuhan's gains were steeper.
- Which company is less exposed to AI disruption, Hanmi or Yuhan?
- Neither Hanmi nor Yuhan faces meaningful AI exposure since both rely on physical drug development and licensing deals that AI tools cannot absorb or replace.
- Does Yuhan's Lazcluze pose a threat to Hanmi?
- There is no direct competitive overlap mentioned between Yuhan's Lazcluze and Hanmi's drug lineup. Lazcluze is instead taking share from AstraZeneca's Tagrisso, a separate company entirely.
Other comparisons with these companies